NASDAQ:MPLT Maplight Therapeutics Q3 2026 Earnings Results & Report $6.54 -0.36 (-5.22%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more. Maplight Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.97 versus the -$1.22 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market OpensConference Call DateNovember 13, 2026Conference Call4:00 PM ET Maplight Therapeutics EPS ResultsActual EPS-$0.97Consensus EPS -$1.22Beat/MissBeat by +$0.25One Year Ago EPSN/AEPS Beat Rate2 of last 5 quartersMaplight Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Maplight Therapeutics Q3 2026 Earnings FAQ Did Maplight Therapeutics beat earnings estimates for Q3 2026? Maplight Therapeutics (NASDAQ:MPLT) reported earnings of -$0.97 per share for Q3 2026, beating the consensus estimate of -$1.22. The report was announced on Monday, November 16, 2026. Maplight Therapeutics Earnings HeadlinesMapLight Moves Toward Phase 3 Schizophrenia Trial; VISTA Study Enrollment ContinuesNovember 16 at 6:28 PM | rttnews.comMapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 16 at 7:15 AM | globenewswire.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 17 at 1:00 AM | Base Camp Trading (Ad)MapLight Therapeutics to Participate in Upcoming Investor ConferenceNovember 9, 2026 | globenewswire.comMapLight: 'Hold' Rating On ML-007C-MA In Schizophrenia And 2nd Half 2027 ADP Data ReadoutOctober 28, 2026 | seekingalpha.comMapLight co-founder is joint winner of 2026 Nobel Prize in MedicineOctober 6, 2026 | seekingalpha.comSee More Maplight Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Maplight Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maplight Therapeutics and other key companies, straight to your email. Email Address About Maplight TherapeuticsMaplight Therapeutics (NASDAQ:MPLT) is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies. The company’s investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.View Maplight Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.